These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33046986)

  • 1. The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis.
    Guo S; Shi Y; Lu S; He Y; Jin G; Zhang S; Li X
    J Cancer; 2020; 11(22):6653-6662. PubMed ID: 33046986
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
    Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
    Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study.
    Schreiber AR; Kagihara J; Eguchi M; Kabos P; Fisher CM; Meyer E; Molina E; Kondapalli L; Bradley CJ; Diamond JR
    Breast Cancer Res Treat; 2022 Jan; 191(2):389-399. PubMed ID: 34705147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and Prognostic Characteristics of Malaysian Triple Negative Breast Cancer Patients Undergoing TAC Chemotherapy Regimen.
    Abdul Aziz AA; Md Salleh MS; Ankathil R
    Int J Breast Cancer; 2020; 2020():8424365. PubMed ID: 32308997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide.
    Sun W; Li C; Liu M; Liu W; Yang C; Cai LI
    Oncol Lett; 2016 Mar; 11(3):2320-2326. PubMed ID: 26998170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
    Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.
    Buyukhatipoglu H; Babacan T; Kertmen N; Balakan O; Suner A; Ates O; Sarici F; Aslan A; Diker O; Tasdemir V; Ozisik Y; Altundag K
    J BUON; 2015; 20(1):22-7. PubMed ID: 25778291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.
    Liao Y; Liao Y; Li J; Xiong J; Fan Y
    Sci Rep; 2020 Apr; 10(1):7349. PubMed ID: 32355298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
    An X; Lei X; Huang R; Luo R; Li H; Xu F; Yuan Z; Wang S; de Nonneville A; Gonçalves A; Houvenaeghel G; Li J; Xue C; Shi Y
    Cancer; 2020 Aug; 126 Suppl 16():3837-3846. PubMed ID: 32710666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
    Lin Y; Wang C; Huang X; Zhou X; Zhou Y; Mao F; Guan J; Song Y; Zhong Y; Xu Y; Sun Q
    Breast Cancer Res Treat; 2019 Jun; 175(3):659-666. PubMed ID: 30937656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of type 2 diabetes mellitus on the prognosis of early stage triple-negative breast cancer in People's Republic of China.
    Ma FJ; Liu ZB; Qu L; Hao S; Liu GY; Wu J; Shao ZM
    Onco Targets Ther; 2014; 7():2147-54. PubMed ID: 25473296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience.
    Khalifa J; Duprez-Paumier R; Filleron T; Lacroix Triki M; Jouve E; Dalenc F; Massabeau C
    Breast J; 2016 Sep; 22(5):510-9. PubMed ID: 27261365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in patients with small node-negative invasive breast cancer.
    Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
    Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology.
    Ntellas P; Spathas N; Agelaki S; Zintzaras E; Saloustros E
    Oncotarget; 2019 Feb; 10(11):1209-1216. PubMed ID: 30838092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
    Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
    Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
    Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
    Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
    Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
    PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.